Athersys says it is working as fast as it can to launch a pivotal trial of its MultiStem® adult-derived “off-the-shelf” stem cell product in acute respiratory distress syndrome (ARDS), after the clinical program received the “Highly Relevant” designation for COVID-19 from BARDA. [Athersys . . .

Get GEN Edge Today!

The post Athersys Stem Cell Therapy Targets Top Cause of COVID-19 Deaths appeared first on GEN – Genetic Engineering and Biotechnology News.